文献速递造血干细胞移植与细胞治疗

伊布替尼一线治疗慢性移植物抗宿主病:随机III期iNTEGRATE研究结果

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
PubMed 文献 · J Clin Oncol · 2023-01-06

iNTEGRATE研究为随机双盲安慰剂对照III期试验,评估伊布替尼联合泼尼松一线治疗中重度慢性移植物抗宿主病(cGVHD)的疗效与安全性。48周缓解率伊布替尼组41%对安慰剂组37%(P=0.54),主要终点未达到,各次要终点均无统计学差异,未观察到新的安全性信号。

要点

  • 伊布替尼联合泼尼松一线治疗cGVHD的48周缓解率为41%,安慰剂联合泼尼松组为37%(P=0.54),主要终点未达到。
  • 中位无事件生存期伊布替尼组15个月对安慰剂组8个月(HR 0.76,95%CI 0.54-1.1,P=0.11),无统计学差异。
  • 两组24个月总生存率均为80%(HR 1.06,95%CI 0.59-1.90),3级及以上严重不良事件发生率分别为49%和47%。

核心结论

  • 伊布替尼联合泼尼松治疗初治cGVHD在主要和次要终点上均未观察到统计学差异,主要终点未达到,未观察到新的安全性信号。

研究设计与样本

  • 随机、双盲、安慰剂对照III期iNTEGRATE研究,纳入年龄≥12岁、新诊断中重度cGVHD、需全身糖皮质激素治疗且既往未接受cGVHD全身治疗的患者,按1:1随机分配至伊布替尼420 mg每日一次联合泼尼松(起始1 mg/kg每日一次)组或安慰剂联合泼尼松组。
  • 伊布替尼联合泼尼松组95例,安慰剂联合泼尼松组98例。
  • 主要终点为根据2014年美国国立卫生研究院共识发展项目标准评估的48周缓解率。

主要发现

  • 48周缓解率伊布替尼联合泼尼松组为41%,安慰剂联合泼尼松组为37%(P=0.54)。
  • 随访33个月时,中位缓解持续时间伊布替尼联合泼尼松组为19个月,安慰剂联合泼尼松组为10个月(P=0.10)。
  • 中位无事件生存期伊布替尼联合泼尼松组为15个月,安慰剂联合泼尼松组为8个月(HR 0.76,95%CI 0.54-1.1,P=0.11)。
  • Lee cGVHD症状量表总体改善率伊布替尼联合泼尼松组为43%,安慰剂联合泼尼松组为31%(P=0.07)。
  • 两组中位总生存期均未达到,24个月Kaplan-Meier总生存率估计两组均为80%(HR 1.06,95%CI 0.59-1.90)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To present primary and final analyses from the randomized, double-blind, placebo-controlled, phase III iNTEGRATE study, which evaluated the safety and efficacy of ibrutinib with prednisone in previously untreated patients with chronic graft-versus-host disease (cGVHD). METHODS: Patients (age ≥ 12 years) with newly diagnosed moderate or severe cGVHD, requiring systemic corticosteroid therapy, and with no prior systemic treatment for cGVHD were randomly assigned 1:1 to receive ibrutinib 420 mg once daily plus prednisone, starting at 1 mg/kg once daily or placebo plus prednisone. The primary end point was response rate at 48 weeks according to 2014 National Institutes of Health Consensus Development Project Criteria. Other end points included event-free survival, duration of response, time to withdrawal of immunosuppressants, improvement in Lee cGVHD Symptom Scale score, overall survival (OS), and safety. RESULTS: Ninety-five and 98 patients enrolled in the ibrutinib-prednisone and placebo-prednisone arms, respectively. At 48 weeks, response rates were 41% (ibrutinib-prednisone) and 37% (placebo-prednisone; P = .54). At 33 months of follow-up, median duration of response was 19 months (ibrutinib-prednisone) and 10 months (placebo-prednisone; P = .10). Median event-free survival was 15 months (ibrutinib-prednisone) and 8 months (placebo-prednisone; hazard ratio, 0.76; 95% CI, 0.54 to 1.1; P = .11). Improvement in overall Lee cGVHD Symptom Scale was 43% (ibrutinib-prednisone) and 31% (placebo-ibrutinib; P = .07). Median OS was not reached in either arm. The 24-month Kaplan-Meier OS estimates were 80% for both arms (hazard ratio, 1.06; 95% CI, 0.59 to 1.90). Grade ≥ 3 serious adverse events occurred in 49% (ibrutinib-prednisone) and 47% (placebo-prednisone) of patients. CONCLUSION: There was no statistical difference observed in the primary and secondary end points with ibrutinib-prednisone treatment. No new safety signals were observed with ibrutinib treatment in previously untreated patients with cGVHD. The primary end point of iNTEGRATE was not met.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Miklos DB, Abu Zaid M, Cooney JP, et al. Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study. J Clin Oncol. 2023. PMID: 36608310. doi:10.1200/JCO.22.00509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。